IMUND Stock Price, News & Analysis
IMUND
OTC
Company Description
Biostax Corp., symbol IMUN, is a pioneering pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical and biotechnology products. Recently, they acquired three Investigational New Drug Applications (IND) for the drug candidate JKB-122, a TLR4 antagonist for autoimmune and inflammatory conditions. Biostax has a strong focus on immunology and nephrology, aiming to provide innovative therapeutic solutions for autoimmune diseases and chronic illnesses.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding
Latest News
SEC Filings
No SEC filings available for IMUND.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the core focus of Biostax Corp.?
Biostax Corp. is focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products with a well-defined market path.
What recent achievement did Biostax Corp. announce regarding JKB-122?
Biostax Corp. announced the acceptance of three Investigational New Drug Applications (IND) for the drug candidate JKB-122, a TLR4 antagonist for autoimmune and inflammatory conditions.
What therapeutic areas does Biostax Corp. concentrate on?
Biostax Corp. has a strong focus on immunology and nephrology, aiming to provide innovative therapeutic solutions for autoimmune diseases and chronic illnesses.
What makes JKB-122 unique as a drug candidate?
JKB-122 is a small molecule and a long-acting TLR4 antagonist that has shown promise in treating chronic liver diseases such as NAFLD, AIH, and NASH.
What is the strategic approach of Biostax Corp. in developing new therapies?
Biostax Corp. uses a hub-and-spoke business model to develop new therapies, focusing on individual product pipelines and disease remission by restoring immune balance.